MetaMax is a private biotechnology company established to develop and promote innovative biopharmaceuticals for the treatment of the most common and dangerous systemic diseases such as cancer, metabolic diseases, and neurological disease.

In August 2011 the Company became a resident of the Biomedical cluster at Skolkovo Innovation Center and in October became a participant of the Technology Platform "Medicine of the Future."

The first product developed by the Company, - MM-D37K - is a chimeric peptide for the treatment of malignant tumors, including glioblastoma, pancreatic cancer, gastrointestinal cancers, melanoma, bladder and liver cancer. Preclinical study of the efficacy showed a high therapeutic potential of this agent against various cancer models (in vitro and in vivo) and demonstrated additive and cumulative effects in combination with standard chemotherapeutic agents.

The Company's drug candidate was listed in TOP-100 inventions in Russia in 2011 issued by the Federal Service for Intellectual Property "Rospatent".